Kevin Feeley Sells 3,855 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,855 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $143.87, for a total transaction of $554,618.85. Following the sale, the chief financial officer owned 8,731 shares of the company’s stock, valued at approximately $1,256,128.97. This represents a 30.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, December 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The shares were sold at an average price of $159.28, for a total transaction of $201,648.48.
• On Wednesday, October 29th, Kevin Feeley sold 388 shares of GeneDx stock. The stock was sold at an average price of $136.54, for a total value of $52,977.52.

GeneDx Stock Performance

Shares of GeneDx stock traded up $0.38 on Thursday, hitting $136.32. The stock had a trading volume of 373,250 shares, compared to its average volume of 877,994. The stock has a market cap of $3.94 billion, a price-to-earnings ratio of 1,514.67 and a beta of 1.99. The company has a quick ratio of 2.59, a current ratio of 2.71 and a debt-to-equity ratio of 0.18. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87. The business’s 50 day moving average is $140.55 and its two-hundred day moving average is $115.36.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.21. The business had revenue of $116.74 million during the quarter, compared to the consensus estimate of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. Analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Guggenheim reaffirmed a “buy” rating and set a $170.00 price target (up from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Wells Fargo & Company set a $155.00 price target on shares of GeneDx and gave the company an “equal weight” rating in a research report on Monday. Piper Sandler increased their price target on GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, September 11th. Finally, Canaccord Genuity Group set a $160.00 price objective on GeneDx and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $134.78.

Institutional Trading of GeneDx

A number of hedge funds have recently made changes to their positions in the company. CIBC Bancorp USA Inc. bought a new stake in shares of GeneDx during the third quarter worth about $216,000. Oberweis Asset Management Inc. raised its holdings in GeneDx by 19.0% in the 3rd quarter. Oberweis Asset Management Inc. now owns 193,920 shares of the company’s stock valued at $20,893,000 after buying an additional 31,020 shares during the last quarter. Castleark Management LLC acquired a new stake in GeneDx during the 3rd quarter worth approximately $7,734,000. PharVision Advisers LLC bought a new stake in GeneDx during the 3rd quarter worth approximately $202,000. Finally, Verition Fund Management LLC increased its position in GeneDx by 25.1% in the 3rd quarter. Verition Fund Management LLC now owns 14,135 shares of the company’s stock valued at $1,523,000 after acquiring an additional 2,840 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.